Comparative Pharmacology
Head-to-head clinical analysis: MENTAX versus MENTAX TC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MENTAX versus MENTAX TC.
MENTAX vs MENTAX-TC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal squalene epoxidase, thereby blocking ergosterol biosynthesis and causing accumulation of squalene, leading to fungal cell death.
MENTAX-TC (butenafine hydrochloride) is a benzylamine antifungal agent that inhibits the synthesis of ergosterol, a critical component of fungal cell membranes, by inhibiting the enzyme squalene epoxidase. This leads to accumulation of squalene and disruption of membrane integrity, resulting in fungal cell death.
Butenafine hydrochloride 1% cream: apply to affected area once daily for 2 weeks for tinea pedis; for tinea corporis and tinea cruris, apply once daily for 1 week.
Apply a thin layer to affected area once daily for 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 5-6 hours; clinical significance: supports twice-daily dosing for topical antifungal therapy.
Terminal elimination half-life is approximately 20 hours (range 16-24 hours), allowing once-daily dosing.
Primarily fecal (biliary) as unchanged drug and metabolites; renal excretion of metabolites accounts for less than 1% of the dose.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine, ~60% in feces as metabolites, <1% in bile as unchanged drug.
Category C
Category C
Topical Antifungal
Topical Antifungal